This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arnold, S. M. Articles by Markesbery, W. R. Search for Related Content PubMed PubMed Citation Articles by Arnold, S. M. Articles by Markesbery, W. R.

Expression of p53, bcl-2, E-Cadherin, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 in Paired Primary Tumors and Brain Metastasis

Division of Hematology and Oncology, Markey Cancer Center [S. M. A., R. K. M.], Department of Surgery, Division of Neurosurgery [A. B. Y., R. A. P.], Sanders-Brown Research Center on Aging [N. N., W. R. M.], and Department of Pathology [W. R. M.], Chandler Medical Center, University of Kentucky, Lexington, Kentucky 40536

The objectives of this study were to: (a) characterize the immunohistochemical expression of p53, bcl-2, E-cadherin (EC), matrix metalloproteinase-9 (MMP-9), and tissue inhibitor of metalloproteinases-1 (TIMP-1) in brain metastases; (b) compare immunohistochemical (IHC) expression of brain metastases with their primary tumors; and (c) assess the prognostic value of expression of these markers. Tumors from 35 patients with brain metastasis were studied for IHC expression of p53, bcl-2, EC, MMP-9, and TIMP-1. In 17 cases, primary tumors were also available for study. In brain metastases, p53 was positive in 91% of cases and intermediate in 9%, MMP-9 was positive in all cases, TIMP-1 was intermediate in 6% and negative in 94% of cases, EC expression was positive in 86% of cases and intermediate in 14%, and bcl-2 was variable. All primary tumors were positive for p53 and MMP-9, 3% were intermediate for TIMP-1 and 97% were negative, 65% were positive for EC and 35% were intermediate, whereas bcl-2 expression was variable. Neither p53, bcl-2, TIMP-1, or EC staining correlated with overall survival or survival with brain metastases. No assessment of survival differences could be made for MMP-9 because of its overexpression in all tissues. This study found that MMP-9 and p53 were markedly overexpressed in primary tumors and matched brain metastasis, TIMP-1 expression was negative in the majority of specimens, whereas EC expression was maintained in both primary tumors and brain metastases and bcl-2 expression was variable. This study suggests that the functional balance of MMP-9 and TIMP-1 is shifted toward extracellular matrix degradation in brain metastases and that deregulation of cell cycle control by p53 also exists in brain metastases. The high expression of EC may indicate the importance of adherence at late stages of metastasis but requires further study.

This article has been cited by other articles:

				H. Grinberg-Rashi, E. Ofek, M. Perelman, J. Skarda, P. Yaron, M. Hajduch, J. Jacob-Hirsch, N. Amariglio, M. Krupsky, D. A. Simansky, et al. The Expression of Three Genes in Primary Non-Small Cell Lung Cancer Is Associated with Metastatic Spread to the Brain Clin. Cancer Res., March 1, 2009; 15(5): 1755 - 1761. [Abstract] [Full Text] [PDF]

				F. Masson, T. Calzascia, W. Di Berardino-Besson, N. de Tribolet, P.-Y. Dietrich, and P. R. Walker Brain Microenvironment Promotes the Final Functional Maturation of Tumor-Specific Effector CD8+ T Cells J. Immunol., July 15, 2007; 179(2): 845 - 853. [Abstract] [Full Text] [PDF]

				R. J. Weil, D. C. Palmieri, J. L. Bronder, A. M. Stark, and P. S. Steeg Breast Cancer Metastasis to the Central Nervous System Am. J. Pathol., October 1, 2005; 167(4): 913 - 920. [Abstract] [Full Text] [PDF]

				N Nathoo, A Chahlavi, G H Barnett, and S A Toms Pathobiology of brain metastases J. Clin. Pathol., March 1, 2005; 58(3): 237 - 242. [Abstract] [Full Text] [PDF]

				O. Ozen, B. Krebs, B. Hemmerlein, A. Pekrun, H. Kretzschmar, and J. Herms Expression of Matrix Metalloproteinases and Their Inhibitors in Medulloblastomas and Their Prognostic Relevance Clin. Cancer Res., July 15, 2004; 10(14): 4746 - 4753. [Abstract] [Full Text] [PDF]

				I. Milas, R. Komaki, T. Hachiya, R. S. Bubb, J. Y. Ro, L. Langford, R. Sawaya, J. B. Putnam, P. Allen, J. D. Cox, et al. Epidermal Growth Factor Receptor, Cyclooxygenase-2, and BAX Expression in the Primary Non-Small Cell Lung Cancer and Brain Metastases Clin. Cancer Res., March 1, 2003; 9(3): 1070 - 1076. [Abstract] [Full Text] [PDF]